Nonalcoholic Fatty Liver Disease

The GALAD score was superior to individual serum markers in detecting hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, according to a case-control study published in Clinical Gastroenterology and Hepatology Journal.

Alcohol use was a significant risk factor for clinically defined nonalcoholic fatty liver disease due to association with alcohol use and liver fat, according to recently published data.

Galectin Therapeutics announced plans for a phase 3 clinical trial of belapectin for patients with nonalcoholic steatohepatitis-related cirrhosis without esophageal varices, according to a press release.

LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, discusses a new artificial intelligence and machine learning tool for nonalcoholic fatty liver disease prediction.

BOSTON — In this exclusive video from The Liver Meeting 2019, Manu Chakravarthy, MD, PhD, chief medical officer and senior vice president of Axcella Health, discusses positive study results from two product candidates including one for nonalcoholic fatty liver disease and one for cirrhosis.

LOS ANGELES — Exercise provides important and varied benefits for individuals with cardiometabolic disorders regardless of experience level, and certain exercise types may yield better outcomes for those with certain conditions, according to a speaker at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

BOSTON — In this exclusive video from The Liver Meeting 2019, Zobair M. Younossi, MD, chairman of the department of medicine at Inova Fairfax Hospital in Virginia, provides an overview of patient reported outcomes from several studies of emerging nonalcoholic fatty liver disease and nonalcoholic steatohepatitis therapies.

Women who developed nonalcoholic fatty liver disease no longer retained the cardiovascular protective effect conferred by female sex, according to a study published in American Journal of Gastroenterology.

Each month Endocrine Today reporters ask leading endocrinologists and diabetes educators about their resesarch and practices. Some of our recent Q&As are below.

Viking Therapeutics announced the initiation of a phase 2b trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist undergoing investigation for patients with nonalcoholic steatohepatitis, according to a press release.